Company / Operating Margin
CytomX Therapeutics, Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-29.3%
FY2025
5-year range
-311.0% / 18.1%
FY2021-FY2025
Trend
-262.2%
vs FY2024
Sector context
#71 of 136
Health Care
What the data says
Operating Margin changed -262% YoY in FY2025, a notable deviation from the 9-year average annual change of -31%.
Based on SEC 10-K filings.
-29.3% in FY2025 with a 5-year CAGR of +19.1%.
Declined from -6.4% to -29.3% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +161.3pp
- 5-Year Change
- +19.1pp
- 10-Year Change
- -
Sector benchmark
#71 of 136 in Health CareTop 52% of 136This company -29.3% Sector average -778.9%
▼
+96.2% above sector average
Key checks
Key Insights
- In FY2025, operating margin decreased 262.2% year-over-year.
- Currently 749.6pp above the Health Care sector average.
- Peak operating margin was recorded in FY2024.
- Lowest operating margin in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -29.3% | -262.2% |
| FY2024 | 18.1% | +382.4% |
| FY2023 | -6.4% | +96.6% |
| FY2022 | -190.6% | +38.7% |
| FY2021 | -311.0% | -542.2% |
| FY2020 | -48.4% | +74.9% |
| FY2019 | -192.9% | -47.4% |
| FY2018 | -130.9% | -102.6% |
| FY2017 | -64.6% | +83.7% |
| FY2016 | -396.1% | +76.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026